• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    9/5/23 1:31:08 PM ET
    $ACER
    $AHG
    $BCDA
    $CBUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate
    Real Estate
    Get the next $ACER alert in real time by email

    Gainers

    • First Wave BioPharma (NASDAQ:FWBI) stock increased by 136.2% to $0.69 during Tuesday's regular session. Trading volume for this security as of 13:30 EST is 37.4 million, which is 2106.0% of its average full-day volume over the last 100 days. The company's market cap stands at $4.8 million.
    • Helius Medical Tech (NASDAQ:HSDT) stock rose 47.69% to $10.9. Trading volume for Helius Medical Tech's stock is 18.1 million as of 13:30 EST. This is 45643.0% of its average full-day volume over the last 100 days. The company's market cap stands at $6.1 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock rose 40.0% to $0.3. The current volume of 178.0 million shares is 631.4% of Novo Integrated Sciences's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $47.4 million.
    • Orgenesis (NASDAQ:ORGS) shares rose 38.79% to $0.81. As of 13:30 EST, Orgenesis's stock is trading at a volume of 229.5K, which is 280.6% of its average full-day volume over the last 100 days. The company's market cap stands at $24.5 million.
    • Cibus (NASDAQ:CBUS) shares moved upwards by 30.78% to $19.5. Cibus's stock is trading at a volume of 158.6K shares as of 13:30 EST. This is 197.5% of its average full-day volume over the last 100 days. The company's market cap stands at $324.5 million.
    • Akso Health Group (NASDAQ:AHG) shares moved upwards by 30.72% to $1.08. Akso Health Group's stock is trading at a volume of 511.3K shares as of 13:30 EST. This is 379.8% of its average full-day volume over the last 100 days. The company's market cap stands at $24.8 million.

    Losers

    • BioCardia (NASDAQ:BCDA) stock decreased by 29.3% to $0.55 during Tuesday's regular session. The current volume of 280.8K shares is 301.5% of BioCardia's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $11.9 million.
    • Acer Therapeutics (NASDAQ:ACER) shares fell 16.54% to $0.95. The current volume of 1.4 million shares is 63.9% of Acer Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $23.2 million.
    • Fresh2 Group (NASDAQ:FRES) shares fell 16.34% to $2.1. The company's market cap stands at $13.1 million.
    • Inspire Veterinary (NASDAQ:IVP) shares fell 15.99% to $2.68. As of 13:30 EST, this security is trading at a volume of 865.0K shares, making up 31.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $32.0 million.
    • Enanta Pharma (NASDAQ:ENTA) stock decreased by 15.41% to $12.47. Trading volume for Enanta Pharma's stock is 656.8K as of 13:30 EST. This is 283.2% of its average full-day volume over the last 100 days. The company's market cap stands at $262.5 million.
    • Vanda Pharma (NASDAQ:VNDA) shares declined by 15.37% to $4.33. As of 13:30 EST, this security is trading at a volume of 3.2 million shares, making up 535.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $248.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACER
    $AHG
    $BCDA
    $CBUS

    CompanyDatePrice TargetRatingAnalyst
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Enanta Pharmaceuticals Inc.
    $ENTA
    11/14/2025Overweight
    Analyst
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Enanta Pharmaceuticals Inc.
    $ENTA
    10/1/2025$20.00Hold → Buy
    Jefferies
    Enanta Pharmaceuticals Inc.
    $ENTA
    7/28/2025$20.00Buy
    H.C. Wainwright
    Vanda Pharmaceuticals Inc.
    $VNDA
    10/31/2024$18.00Buy
    H.C. Wainwright
    Cibus Inc.
    $CBUS
    7/29/2024$25.00Buy
    Alliance Global Partners
    Cibus Inc.
    $CBUS
    7/19/2024$22.00Buy
    Canaccord Genuity
    More analyst ratings

    $ACER
    $AHG
    $BCDA
    $CBUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACER
    $AHG
    $BCDA
    $CBUS
    SEC Filings

    View All

    SEC Form 6-K filed by Akso Health Group

    6-K - Akso Health Group (0001702318) (Filer)

    3/23/26 4:40:01 PM ET
    $AHG
    Real Estate

    SEC Form 10-K filed by Cibus Inc.

    10-K - Cibus, Inc. (0001705843) (Filer)

    3/17/26 4:36:42 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Cibus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cibus, Inc. (0001705843) (Filer)

    3/17/26 4:09:34 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    $ACER
    $AHG
    $BCDA
    $CBUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $AHG
    $BCDA
    $CBUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

    SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10207584/1039b7a7360. Please note that registered participants will receive their dial-in number upon registration. For those who have not

    3/19/26 7:47:51 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

    WASHINGTON, March 19, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, today voiced serious concerns over the U.S. Food and Drug Administration (FDA)'s new draft guidance, "General Considerations for the Use of New Approach Methodologies in Drug Development," released March 18, 2026, by the Center for Drug Evaluation and Research (CDER). The FDA's draft guidance aims to support the use of New Approach Methodologies (NAMs)—advanced non-animal tools like in v

    3/19/26 4:34:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cibus Reports Fourth Quarter Financial Results and Provides Business Update

    SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced its financial results for the quarter ended December 31, 2025, and provided a business update. Management will host a conference call and webcast today at 4:30 p.m. ET. Management Commentary Peter Beetham, Interim Chief Executive Officer of Cibus, commented, "2025 was a landmark year that validated our technology leadership and strategic vision. Our seven Rice partner customers continue to drive our near-term 2027 and 2028 commercial launch targets in our USA and LATAM geographic marke

    3/17/26 4:05:00 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    $ACER
    $AHG
    $BCDA
    $CBUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Enanta Pharmaceuticals

    Analyst initiated coverage of Enanta Pharmaceuticals with a rating of Overweight

    11/14/25 11:26:32 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $AHG
    $BCDA
    $CBUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Akso Health Group

    3 - Akso Health Group (0001702318) (Issuer)

    3/18/26 5:27:12 PM ET
    $AHG
    Real Estate

    SEC Form 4 filed by Broos Carlo

    4 - Cibus, Inc. (0001705843) (Issuer)

    3/18/26 11:43:50 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    SEC Form 4 filed by Sauer Noel

    4 - Cibus, Inc. (0001705843) (Issuer)

    3/18/26 11:39:49 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    $ACER
    $AHG
    $BCDA
    $CBUS
    Leadership Updates

    Live Leadership Updates

    View All

    BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

    SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Dir

    11/24/25 8:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cibus Announces the Election of Craig Wichner to Board of Directors

    SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the election of Craig Wichner to its Board of Directors. Mr. Wichner will also serve as a member of the Board's current Strategy Committee. "Craig brings an exceptional combination of financial acumen, strategic discipline, and industry insight to the Cibus Board," said Mark Finn, Chairman of the Board of Cibus. "As Cibus prepares for anticipated commercial scaling of our trait platform, Craig's expertise in sustainable growth and capital strategy in agriculture will be instrumental in strengthening our

    11/11/25 7:00:00 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Solana Company Executive Chairman's Message: October 20th, 2025

    NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel

    10/20/25 10:18:15 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ACER
    $AHG
    $BCDA
    $CBUS
    Financials

    Live finance-specific insights

    View All

    BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

    SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10207584/1039b7a7360. Please note that registered participants will receive their dial-in number upon registration. For those who have not

    3/19/26 7:47:51 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cibus to Report Fourth Quarter 2025 Financial Results on March 17, 2026 After the Market Close and Host Conference Call

    SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report fourth quarter 2025 financial results on Tuesday, March 17, 2026. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Fourth Quarter 2025 Results Conference Call Event Date: Tuesday, March 17, 2026Time: 4:30 p.m. ETParticipant Numbers: +1-800-343-5172 (U.S.), +1-203-518-9856 (International)The conference ID "CIBUS" or 24287 will be required for entryEv

    3/3/26 4:05:00 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $AHG
    $BCDA
    $CBUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:51:18 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:50:26 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    11/14/24 4:03:02 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care